Co-infection in COVID19 infection: UK experience [COVID-19]

  • Research type

    Research Study

  • Full title

    A retrospective observational study of co-infections in adults with COVID-19 pneumonia in the United Kingdom.

  • IRAS ID

    284341

  • Contact name

    Wei Shen Lim

  • Contact email

    WeiShen.Lim@nuh.nhs.uk

  • Sponsor organisation

    Nottingham University Hospitals NHS Trust

  • Duration of Study in the UK

    0 years, 7 months, 30 days

  • Research summary

    COVID19 is a potentially life-threatening respiratory disease caused by a novel coronavirus, SARS-CoV-2, which has spread globally since December 2019. In previous pandemics caused by influenza viruses, a number of patients were also co-infected with bacteria and were more likely to develop severe illness and to die. As bacteria are becoming increasingly resistant to antimicrobial drugs, it is therefore important to gain an understanding of the numbers and types of co-infections occurring in COVID19 patients so that antimicrobials can be used most appropriately in these patients. \n\nCurrently much of the published information on co-infections in COVID19 originates from China where the first patients were observed, but these data may not be generalisable to the UK. In this study we will evaluate what proportion of adult patients who require intensive care for COVID19 pneumonia also have a co-infection and the types of co-pathogens involved (bacteria, fungi or other viruses). We will also identify antimicrobial resistance in bacterial pathogens. \n\nAdults over 16 years old with laboratory-confirmed COVID19 pneumonia who have completed an admission on a participating intensive care unit (ICU) are eligible for inclusion. Seven hospitals across England are contributing data. Anonymised, routinely collected clinical and microbiological data is entered via a secure online database platform called RedCAP Cloud. No patient identifiable data is entered or available to the researcher at the point of analysis. Analysis of data collected to 13 May 2020 will help to inform the development of a UK rapid guideline on antibiotics in COVID19 pneumonia.

  • REC name

    North East - York Research Ethics Committee

  • REC reference

    20/NE/0183

  • Date of REC Opinion

    22 Jul 2020

  • REC opinion

    Further Information Favourable Opinion